Volume 17 Supplement 1
Publication of this supplement was funded by the WHO. Information about the source of funding for specific projects can be found in the individual articles. The articles have undergone the journal's standard peer review process for supplements. PE is a WHO staff member and has no financial conflicts of interest. RC has received funding from the U.S. Agency for Healthcare Research and Quality to conduct systematic reviews on hepatitis C screening. MH receives funding from the NHMRC in Australia for a Principal Research Fellowship. The Burnet Institute receives funding from Gilead Science, Abbvie and BMS for investigator initiated research, for which MH is the lead investigator, and receives support from the Victorian Government through the Victorian Operational Infrastructure Support Program. PH is an employee of BioMed Central. The Supplement Editors declare that they were not involved in the peer review process for any paper on which they are an author.
Edited by Philippa Easterbrook, Roger Chou, Margaret Hellard and Philippa Harris
Linking persons with hepatitis B (HBV) and hepatitis C (HCV) infection with appropriate prevention and treatment requires that they first be diagnosed. The World Health Organization (WHO) has developed its fir...
Chronic Hepatitis B Virus (HBV) infection is characterised by the persistence of hepatitis B surface antigen (HBsAg). Expanding HBV diagnosis and treatment programmes into low resource settings will require hi...
Although direct-acting antivirals can achieve sustained virological response rates greater than 90% in Hepatitis C Virus (HCV) infected persons, at present the majority of HCV-infected individuals remain undia...
Initial serological testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is conducted using either rapid diagnostic tests (RDT) or laboratory-based enzyme immunoassays (EIA)s for d...
The detection and quantification of hepatitis B (HBV) DNA and hepatitis C (HCV) RNA in whole blood collected on dried blood spots (DBS) may facilitate access to diagnosis and treatment of HBV and HCV infection...
Dried blood spots (DBS) are a convenient tool to enable diagnostic testing for viral diseases due to transport, handling and logistical advantages over conventional venous blood sampling. A better understandin...
Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral ...
Hepatitis C virus (HCV) infection represents a major public health burden with diverse epidemics worldwide, but at present, only a minority of infected persons have been tested and are aware of their diagnosis...
There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatit...
Approximately 8% of HIV-infected individuals are co-infected with hepatitis B virus (HBV) in sub-Saharan Africa (SSA). Knowledge of HBV status is important to guide optimal selection of antiretroviral therapy ...
Access to hepatitis B virus (HBV) and hepatitis C virus (HCV) diagnostics remains a key bottleneck in scale-up of access to HBV and HCV treatment, particularly in low- and middle-income countries (LMICs) that ...
The current low access to virological testing to confirm chronic viraemic HCV infection in low- and middle-income countries (LMIC) is limiting the rollout of hepatitis C (HCV) care. Existing tests are complex,...
Innovation contests are a novel approach to elicit good ideas and innovative practices in various areas of public health. There remains limited published literature on approaches to deliver hepatitis testing. ...
A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most pe...
Citation Impact 2023
Journal Impact Factor: 3.4
5-year Journal Impact Factor: 3.3
Source Normalized Impact per Paper (SNIP): 1.106
SCImago Journal Rank (SJR): 1.031
Speed 2023
Submission to first editorial decision (median days): 13
Submission to acceptance (median days): 148
Usage 2023
Downloads: 6,949,317
Altmetric mentions: 28,444
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication